Caroline Seymour

Narendranath Epperla, MD, MS, reflects on recent advances in Hodgkin lymphoma and non-Hodgkin lymphoma.

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Atif Hussein, MD, discusses how the treatment of patients with hepatocellular carcinoma and cholangiocarcinoma has evolved in recent years.

Ulka Vaishampayan, MD, discusses the historical management of patients with metastatic renal cell carcinoma and how advances with systemic therapy have impacted the sequencing of cytoreductive nephrectomy in the treatment paradigm.

Celestia S. Higano, MD, FACP, provides perspective on data from the CARD trial and their implications on clinical practice.

Hussein Aoun, MD, discusses the use of novel imaging modalities and contrasted them with conventional imaging tools in prostate cancer.

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

Clara Hwang, MD, discusses key trials that have shaped the current treatment paradigms of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer.

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

Anthony R. Mato, MD, MSCE, discusses recent treatment advances that have been made in the frontline and relapsed/refractory settings of chronic lymphocytic leukemia.

Jeff P. Sharman, MD, discusses updated data from the ELEVATE-TN trial and ongoing research that is poised to define the optimal role of acalabrutinib in chronic lymphocytic leukemia.

Hope S. Rugo, MD, FASCO, discusses the research being done to develop more effective therapies for patients with advanced hormone receptor–positive, HER2-negative breast cancer who harbor an ESR1 mutation.

Jae H. Park, MD, discusses how emerging agents across several treatment modalities are demonstrating great potential in acute lymphoblastic leukemia.

Sagar Lonial, MD, FACP, discusses important additions to the treatment arsenal in relapsed/refractory multiple myeloma.

Mark E. Robson, MD, provides a snapshot of the precision focus in breast cancer, as well as the emergence of biosimilars in the field.

Select DNA variants leading to methylation dysregulation within the germline DNA of men with localized prostate cancer were found to be predictive of disease biology, suggesting the prognostic capacity of inherited elements of a patient’s genome, according to data published in Nature Medicine.

Thomas G. Martin, MD, provides insight into novel therapies under evaluation in relapsed/refractory multiple myeloma and the steps that need to be taken prior to and upon the use of these approaches in clinical practice.

Lee S. Schwartzberg, MD, FACP, discusses paradigm shifts in hormone receptor–positive breast cancer and triple-negative breast cancer.

Jamie E. Chaft, MD, explains how the PACIFIC trial has impacted the treatment of patients with stage III unresectable non–small cell lung cancer and the research being done to move immunotherapy into the neoadjuvant setting.

Floor J. Backes, MD, discusses subtle differences among PARP inhibitors that can help determine their optimal use in advanced ovarian cancer.

Nisha A. Mohindra, MD, detailed current treatment strategies and some of the next-generation inhibitors that could shift sequencing approaches in ALK-positive and ROS1-positive non–small cell lung cancer.

Lee S. Schwartzberg, MD, FACP, discusses the development and approval process for biosimilars and explains how their availability could drive down out-of-pocket costs for patients.